title: Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis.
abstract: OBJECTIVE
  The objective of the study was to evaluate the regression, relapse, and live birth rates of early-stage endometrial cancer (EC) and atypical complex hyperplasia (ACH) with fertility-sparing treatment.
  
  
  METHODS
  This was a metaanalysis of the proportions from observational studies with a random-effects model and a meta-regression to explore for heterogeneity.
  
  
  RESULTS
  Thirty-four observational studies, evaluating the regression, relapse, and live birth rates of early-stage EC (408 women) and ACH (151 women) with fertility-sparing treatment. Fertility-sparing treatment for EC achieved a pooled regression rate of 76.2%, a relapse rate of 40.6%, and a live birth rate of 28%. For ACH the pooled regression rate was 85.6%, a relapse rate of 26%, and a live birth rate of 26.3%. Twenty women were diagnosed with ovarian cancer (concurrent or metastatic) during follow-up (3.6%) and 10 progressed to higher than stage I EC (1.9%) from which 2 women died.
  
  
  CONCLUSIONS
  Fertility-sparing treatment of EC and ACH is feasible and selected women can satisfy their reproductive wishes.
authors.affiliation: Academic Unit of Obstetrics and Gynaecology, Birmingham Women's Hospital, Birmingham, England, United Kingdom. ioannis.gallos@nhs.net
authors.forename: Ioannis D
authors.initials: ID
authors.lastname: Gallos
authors.forename: Jason
authors.initials: J
authors.lastname: Yap
authors.forename: Madhurima
authors.initials: M
authors.lastname: Rajkhowa
authors.forename: David M
authors.initials: DM
authors.lastname: Luesley
authors.forename: Arri
authors.initials: A
authors.lastname: Coomarasamy
authors.forename: Janesh K
authors.initials: JK
authors.lastname: Gupta
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D000328:Adult; D001723:Birth Rate; D004714:Endometrial Hyperplasia / Q000473:pathology / Q000628:therapy*; D016889:Endometrial Neoplasms / Q000473:pathology / Q000628:therapy*; D005260:Female; D005298:Fertility; D006801:Humans; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome